Mednax To Change Name to Pediatrix Medical Group, Inc. Effective July 1, 2022
21 Juni 2022 - 12:45PM
Business Wire
Mednax, Inc. (NYSE: MD) today announced that it will change its
corporate name to Pediatrix Medical Group, Inc., effective after
the close of the market on July 1, 2022. The Company’s common stock
will continue to trade on the New York Stock Exchange under the
current ticker symbol “MD.”
“We are excited to complete this full return to Pediatrix, a
nationally well-known and highly respected name,” said Mark S.
Ordan, Mednax’s Chief Executive Officer. “This underscores our
position as a leading provider of care to women, babies, and
children; an employer of choice; and a trusted partner to hospitals
and clinicians across the country.”
No action is necessary on the part of shareholders in connection
with the name change; existing certificates that represent shares
of Mednax, Inc. common stock will continue to represent shares of
Pediatrix Medical Group, Inc. after the name change.
ABOUT MEDNAX
Mednax, Inc. is a national medical group comprised of the
nation’s leading providers of physician services practicing under
the Pediatrix® brand. Pediatrix-affiliated clinicians are committed
to providing coordinated, compassionate and clinically excellent
services to women, babies and children across the continuum of
care, both in hospital settings and office-based practices.
Specialties include obstetrics, maternal-fetal medicine and
neonatology complemented by 18 pediatric subspecialties, as well as
a newly expanded area of primary and urgent care clinics. The
group’s high-quality, evidence-based care is bolstered by
investments in research, education, quality-improvement and safety
initiatives. The company was founded in 1979 as a single affiliated
neonatology practice and today provides its highly focused and
often critical care services through more than 4,700 affiliated
physicians and other clinicians in 38 states and Puerto Rico. To
learn more about Pediatrix, visit www.pediatrix.com or follow us on
Facebook, Instagram, LinkedIn, Twitter and the Pediatrix blog.
Mednax investment information can be found at
www.mednax.com/investors.
Certain statements and information in this press release may be
deemed to contain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended (the “Securities Act”),
and Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may include, but are not limited to,
statements relating to the Company’s objectives, plans and
strategies, and all statements, other than statements of historical
facts, that address activities, events or developments that we
intend, expect, project, believe or anticipate will or may occur in
the future. These statements are often characterized by terminology
such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,”
“plan,” “will,” “expect,” “estimate,” “project,” “positioned,”
“strategy” and similar expressions, and are based on assumptions
and assessments made by the Company’s management in light of their
experience and their perception of historical trends, current
conditions, expected future developments and other factors they
believe to be appropriate. Any forward-looking statements in this
press release are made as of the date hereof, and the Company
undertakes no duty to update or revise any such statements, whether
as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties. Important factors that
could cause actual results, developments, and business decisions to
differ materially from forward-looking statements are described in
the Company’s most recent Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q, including the sections entitled
“Risk Factors”, as well the Company’s current reports on Form 8-K,
filed with the Securities and Exchange Commission, and include the
impact of the Company’s name change; the impact of the COVID-19
pandemic on the Company and its financial condition and results of
operations; the effects of economic conditions on the Company’s
business; the effects of the Affordable Care Act and potential
changes thereto or a repeal thereof; the Company’s relationships
with government-sponsored or funded healthcare programs, including
Medicare and Medicaid, and with managed care organizations and
commercial health insurance payors; the impact of surprise billing
legislation; the Company’s ability to comply with the terms of its
debt financing arrangements; the Company’s transition to a
third-party revenue cycle management provider; the impact of the
divestiture of the Company’s anesthesiology and radiology medical
groups; the impact of management transitions; the timing and
contribution of future acquisitions; the effects of share
repurchases; and the effects of the Company’s transformation
initiatives, including its reorientation on, and growth strategy
for, its pediatrics and obstetrics business.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220621005373/en/
Charles Lynch Senior Vice President, Finance and Strategy
954-384-0175, x 5692 charles_lynch@mednax.com
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Pediatrix Medical (NYSE:MD)
Historical Stock Chart
Von Mär 2023 bis Mär 2024